Remdesivir brought in $873 million in the quarter, below analysts’ estimates of $960 million, according to Refinitiv IBES data. Gilead Chief Commercial Officer Johanna Mercier said that although the United States saw a surge in COVID-19 cases over the summer, many were younger people and hospitalization rates actually dropped. “Our assumption is in light of the surge this fall both in Europe and the U.S., those numbers will pop back up,” she said. …read more
Source:: Yahoo Finance
